Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Hepion Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
HEPA
Nasdaq
2830
hepionpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
- Jan 22nd, 2025 1:00 pm
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
- Dec 11th, 2024 1:00 pm
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
- Dec 5th, 2024 1:30 pm
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
- Dec 2nd, 2024 1:00 pm
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
- Nov 11th, 2024 1:00 pm
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
- Sep 4th, 2024 1:25 pm
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
- Jul 22nd, 2024 12:00 pm
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
- Apr 19th, 2024 8:30 pm
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
- Mar 6th, 2024 1:30 pm
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
- Feb 16th, 2024 1:00 pm
Scroll